Safety of intravenous (IV) NEPA and oral NEPA for prevention of CINV in patients (pts) with breast cancer (BC) receiving anthracycline/cyclophosphamide (AC) chemotherapy (CT).

被引：0
|
作者：
Schwartzberg, Lee S.
Voisin, Daniel
Rizzi, Giada
Patel, Kamal
Aapro, Matti S.
机构：
[1] West Canc Ctr, Memphis, TN USA
[2] Helsinn Healthcare SA, Lugano, Switzerland
[3] CARTI Canc Ctr, Little Rock, AR USA
[4] Clin Genolier, Genolier, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11594
引用
收藏
页数：2
相关论文
共 50 条
  • [21] SAFETY AND EFFICACY OF INTRAVENOUS (IV) NEPA, A NOVEL FIXED ANTIEMETIC COMBINATION OF FOSNETUPITANT AND PALONOSETRON, FOR PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) OVER MULTIPLE CYCLES OF HIGHLY EMETOGENIC CHEMOTHERAPY (HEC)
    Clark-Snow, Rebecca
    Koesel, Nicole
    Rittenberg, Cynthia
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [22] Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer
    Nawa-Nishigaki, Minako
    Kobayashi, Ryo
    Suzuki, Akio
    Hirose, Chiemi
    Matsuoka, Rie
    Mori, Ryutaro
    Futamura, Manabu
    Sugiyama, Tadashi
    Yoshida, Kazuhiro
    Itoh, Yoshinori
    ANTICANCER RESEARCH, 2018, 38 (02) : 877 - 884
  • [23] Efficacy of intravenous NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies
    Aapro, Matti
    Navari, Rudolph M.
    Roeland, Eric
    Zhang, Li
    Schwartzberg, Lee
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 157
  • [24] Safety and efficacy of tow-dose pegfilgrastim (pegfil) in maintaining chemotherapy (CT) dose density in patients (pts) receiving docetaxel/doxorubicin/cyclophosphamide (TAC) or doxorubicin/cyclophosphamide (AC) as neoadjuvant chemotherapy (NCT) for stage II-III breast cancer (BC)
    Kim, E.
    Jin, R.
    Choi, K.
    Frankel, P. H.
    Somlo, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] Efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC)
    Aapro, M.
    Rossi, G.
    Rizzi, G.
    Borroni, M. E.
    Lorusso, V.
    Karthaus, M.
    Grunberg, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S266 - S266
  • [26] Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy
    Schwartzberg, L.
    Roeland, E.
    Andric, Z.
    Kowalski, D.
    Radic, J.
    Voisin, D.
    Rizzi, G.
    Navari, R.
    Gralla, R. J.
    Karthaus, M.
    ANNALS OF ONCOLOGY, 2018, 29 (07) : 1535 - 1540
  • [27] Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy
    Kurteva, Galina
    Chilingirova, Nataliya
    Rizzi, Giada
    Caccia, Tatiana
    Stell, Valentino
    Bernareggi, Alberto
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 139
  • [28] NEPA <sc>(</sc>Netupitant/Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial
    Navari, Rudolph M.
    Bonizzoni, Erminio
    CANCER MEDICINE, 2025, 14 (07):
  • [29] Real-World Evidence of the Effectiveness and Safety of NEPA (Netupitant-Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients (PTS) Receiving Highly (HEC) or Moderately Emetogenic Chemotherapy (MEC): Final Results of a German Prospective Non-Interventional Study
    Karthaus, Meinolf
    Klare, Peter
    Oskay-Oezcelik, Guelten
    Heilmann, Volker
    Wierick, Elke
    Wuelfing, Pia
    Hielscher, Carsten
    Guth, Dagmar
    Zahn, Mark-Oliver
    Hanusch, Claus
    Hesse, Joachim
    Jungberg, Peter
    Kurbacher, Christian
    Neef, Ute
    Schilling, Joerg
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 182 - 182
  • [30] Safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving breast cancer resistant protein (BCRP) substrate chemotherapy agents
    Schwartzberg, L.
    Jordan, K.
    Rapoport, B. L.
    Schnadig, I.
    Chasen, M.
    Arora, S.
    Barbour, S.
    Powers, D.
    Navari, R.
    ANNALS OF ONCOLOGY, 2016, 27
12345